Probiotics, postbiotics, and synbiotics in the prevention of oncological diseases

Czech version

Authors: P. Bořilová Linhartová ^1,2; D. Száraz ²
Authors‘ workplace: RECETOX, PřF MU, Brno2 Klinika ústní, čelistní a obličejové chirurgie LF MU a FN Brno ¹
Published in: Klin Onkol 2026; 39(Supplementum 1): 67-71
Category: Review
doi: https://doi.org/10.48095/ccko2026S67

Overview

Background: In the context of oncological diseases of (not only) the gastrointestinal tract and the oral cavity, the role of microorganisms is being increasingly discussed and investigated. A growing body of evidence supports the significance of specific microbial strains and their products both in the etiopathogenesis of certain cancers and in their prevention and therapy. Aim: This review summarizes recent findings on the targeted modulation of the human microbiota using probiotics (including Bifidobacteria, Lactobacilli, etc.), their products (postbiotics, e. g. butyrate), and formulations combining probiotics with prebiotics (synbiotics), in the context of cancer prevention and progression, adverse effects of anticancer therapy, and associated complications related to the disease and surgical treatment. The results of clinical studies demonstrate the benefits of these preparations, particularly in preventing and alleviating gastrointestinal symptoms and postoperative infectious complications, as well as inflammatory mucosal damage (including oral mucositis) in oncology patients, with multi-strain probiotic formulations demonstrating greater efficacy. Research is even underway in animal models to explore the use of probiotics in immunotherapy. Despite the promising results obtained from modulating the human microbiota to improve the quality of life of cancer patients, as well as for cancer prevention and potentially even therapy, broader clinical implementation is limited by interindividual variability of the microbiome, safety concerns in immunocompromised patients, and the insufficiently documented quality of some available products. Nevertheless, given the undeniable mechanistic and translational potential of probiotic, postbiotic, and synbiotic supplementation, continued clinical research in this field is highly warranted.

Keywords:

dysbiosis – Preventive medicine – Quality of life – neoplasms – probiotics – synbiotics – butyrates

Sources

1. Zitvogel L, Kroemer G. Cancer and the metaorganism. Cancer Discov 2024; 14 (4): 658–662. doi: 10.1158/2159-8290.CD-23-1484.

2. Vyhnalova T, Danek Z, Gachova D et al. The role of the oral microbiota in the etiopathogenesis of oral squamous cell carcinoma. Microorganisms 2021; 9 (8): 1549. doi: 10.3390/microorganisms9081549.

3. Chen C, Su Q, Zi M et al. Harnessing gut microbiota for colorectal cancer therapy: from clinical insights to therapeutic innovations. NPJ Biofilms Microbiomes 2025; 11 (1): 190. doi: 10.1038/s41522-025-00818-3.

4. Wei H, Yue Z, Han J et al. Oral compound probiotic supplements can improve the quality of life for patients with lung cancer during chemotherapy: a randomized placebo-controlled study. Thorac Cancer 2024; 15 (2): 182–191. doi: 10.1111/1759-7714.15177.

5. Deleemans JM, Gajtani Z, Baydoun M et al. The use of prebiotic and probiotic interventions for treating gastrointestinal and psychosocial health symptoms in cancer patients and survivors: a systematic review. Integr Cancer Ther 2021; 20 : 15347354211061733. doi: 10.1177/15347354211061733.

6. Food and Agricultural Organization of the United Nations and World Health Organization. Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. [online]. Available from: https: //www.researchgate.net/publication/237102730_Health_and_Nutritional_Properties_of_Probiotics_in_Food_Including_Powder_Milk_with_Live_Lactic_Acid_Bacteria_-_Joint_FAOWHO_Expert_Consultation.

7. Śliżewska K, Markowiak-Kopeć P, Śliżewska W. The role of probiotics in cancer prevention. Cancers (Basel) 2020; 13 (1): 20. doi: 10.3390/cancers13010020.

8. Ichikawa Y, Yamamoto H, Hirano SI et al. The overlooked benefits of hydrogen-producing bacteria. Med Gas Res 2023; 13 (3): 108–111. doi: 10.4103/2045-9912.344977.

9. van Zyl WF, Deane SM, Dicks LMT. Molecular insights into probiotic mechanisms of action employed against intestinal pathogenic bacteria. Gut Microbes 2020; 12 (1): 1831339. doi: 10.1080/19490976.2020.1831339.

10. Larson PJ, Zhou W, Santiago A et al. Associations of the skin, oral and gut microbiome with aging, frailty and infection risk reservoirs in older adults. Nat Aging 2022; 2 (10): 941–955. doi: 10.1038/s43587-022-00287-9.

11. Salvi PS, Cowles RA. Butyrate and the intestinal epithelium: modulation of proliferation and inflammation in homeostasis and disease. Cells 2021; 10 (7): 1775. doi: 10.3390/cells10071775.

12. Tegegne BA, Abebaw D, Teffera ZH et al. Microbial therapeutics in cancer: translating probiotics, prebiotics, synbiotics, and postbiotics from mechanistic insights to clinical applications: a topical review. FASEB J 2025; 39 (20): e71146. doi: 10.1096/fj.202502118R.

13. Yang B, Li W, Shi J. Preventive effect of probiotics on oral mucositis induced by anticancer therapy: a systematic review and meta-analysis of randomized controlled trials. BMC Oral Health 2024; 24 (1): 1159. doi: 10.1186/s12903-024-04955-7.

14. Rivera C. Understanding the potential of probiotics in oral cancer prevention: a short review on microbial modulation. Discov Oncol 2025; 17 (1): 4. doi: 10.1007/s12672-025-04020-x.

15. Manifar S, Koopaie M, Jahromi ZM et al. Effect of synbiotic mouthwash on oral mucositis induced by radiotherapy in oral cancer patients: a double-blind randomized clinical trial. Support Care Cancer 2022; 31 (1): 31. doi: 10.1007/s00520-022-07521-5.

16. Zhang JW, Du P, Gao J et al. Preoperative probiotics decrease postoperative infectious complications of colorectal cancer. Am J Med Sci 2012; 343 (3): 199–205. doi: 10.1097/MAJ.0b013e31823aace6.

17. Gianotti L, Morelli L, Galbiati F et al. A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients. World J Gastroenterol 2010; 16 (2): 167–175. doi: 10.3748/wjg.v16.i2.167.

18. Stene C, Xu J, Fallone de Andrade S et al. Synbiotics protected radiation-induced tissue damage in rectal cancer patients: a controlled trial. Clin Nutr 2025; 49 : 33–41. doi: 10.1016/j.clnu.2025.03.025.

19. Chen Y, Qi A, Teng D et al. Probiotics and synbiotics for preventing postoperative infectious complications in colorectal cancer patients: a systematic review and meta-analysis. Tech Coloproctol 2022; 26 (6): 425–436. doi: 10.1007/s10151-022-02585-1.

20. Li X, Gong W, Tang K et al. The effect of oral nutritional supplementation combined with probiotics on the liver function and intestinal microflora in lung cancer chemotherapy patients through the gut-liver axis. Sci Rep 2025; 15 (1): 10063. doi: 10.1038/s41598-025-95005-x.

21. Motoori M, Sugimura K, Tanaka K et al. Comparison of synbiotics combined with enteral nutrition and prophylactic antibiotics as supportive care in patients with esophageal cancer undergoing neoadjuvant chemotherapy: a multicenter randomized study. Clin Nutr 2022; 41 (5): 1112–1121. doi: 10.1016/j.clnu.2022.03.023.

22. Motoori M, Yano M, Miyata H et al. Randomized study of the effect of synbiotics during neoadjuvant chemotherapy on adverse events in esophageal cancer patients. Clin Nutr 2017; 36 (1): 93–99. doi: 10.1016/j.clnu.2015.11.008.

23. Liu Y, Jia M. Shenqi injection plus probiotics improves nutritional status in patients with gastric cancer after partial gastrectomy. Pak J Pharm Sci 2024; 37 (6): 1223–1228.

24. Xiong H, He Z, Wei Y et al. Probiotic compounds enhanced recovery after surgery for patients with distal gastric cancer: a prospective, controlled clinical trial. Ann Surg Oncol 2024; 31 (8): 5240–5251. doi: 10.1245/s10434-024-15394-7.

25. Maher S, Elmeligy HA, Aboushousha T et al. Synergistic immunomodulatory effect of synbiotics pre -⁠ and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study. Cancer Immunol Immunother 2024; 73 (6): 109. doi: 10.1007/s00262-024-03686-6.

26. Tang G, Zhang L, Huang W et al. Probiotics or synbiotics for preventing postoperative infection in hepatopancreatobiliary cancer patients: a meta-analysis of randomized controlled trials. Nutr Cancer 2022; 74 (10): 3468–3478. doi: 10.1080/01635581.2022.2089698.

27. Ki Y, Kim W, Nam J et al. Probiotics for rectal volume variation during radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2013; 87 (4): 646–650. doi: 10.1016/j.ijrobp.2013.07.038.

28. Linn YH, Thu KK, Win NH. Effect of probiotics for the prevention of acute radiation-induced diarrhoea among cervical cancer patients: a randomized double--blind placebo-controlled study. Probiotics Antimicrob Proteins 2019; 11 (2): 638–647. doi: 10.1007/s12602-018-9408-9.

29. De Loera Rodríguez LH, Ortiz GG, Rivero Moragrega P et al. Effect of symbiotic supplementation on fecal calprotectin levels and lactic acid bacteria, Bifidobacteria, Escherichia coli and Salmonella DNA in patients with cervical cancer. Nutr Hosp 2018; 35 (6): 1394–1400. doi: 10.20960/nh.1762.

30. Masuda H, Tanabe Y, Sakai H et al. Efficacy of probiotics and trimebutine maleate for abemaciclib-induced diarrhea: a randomized, open-label phase II trial (MERMAID, WJOG11318B). Breast 2023; 71 : 22–28. doi: 10.1016/j.breast.2023.07.003.

31. Zeng F, Wang B, Peng M et al. Comparison of clinical--radiological and radiomics features for predicting pulmonary nodule malignancy in a multicenter study of mixed clinical and surveillance populations. Eur Radiol 2026. [Ahead of Print]. doi: 10.1007/s00330-026-12437-3.

32. Sun J, Song S, Liu J et al. Gut microbiota as a new target for anticancer therapy: from mechanism to means of regulation. NPJ Biofilms Microbiomes 2025; 11 (1): 43. doi: 10.1038/s41522-025-00678-x.

33. Rebeck ON, Wallace MJ, Prusa J et al. A yeast-based oral therapeutic delivers immune checkpoint inhibitors to reduce intestinal tumor burden. Cell Chem Biol 2025; 32 (1): 98.e7–110.e7. doi: 10.1016/j.chembiol.2024.10.013.

34. Bender MJ, McPherson AC, Phelps CM et al. Dietary tryptophan metabolite released by intratumoral lactobacillus reuteri facilitates immune checkpoint inhibitor treatment. Cell 2023; 186 (9): 1846.e26–1862.e26. doi: 10.1016/j.cell.2023.03.011.

35. Huo R, Xu QG, You YQ et al. Bifidobacterium boosts anti-PD-1 effectiveness through JAK pathway in hepatocellular carcinoma. NPJ Precis Oncol 2025; 9 (1): 251. doi: 10.1038/s41698-025-00960-3.

36. Nařízení Evropského parlamentu a Rady (EU) 2017/745 ze dne 5. dubna 2017 o zdravotnických prostředcích, změně směrnice 2001/83/ES, nařízení (ES) č. 178/2002 a nařízení (ES) č. 1223/2009 a o zrušení směrnic Rady 90/385/EHS a 93/42/EHS. Úřední věstník Evropské unie 2017; 60 : 1–175.

37. Mego M, Zajac V. Probiotiká v onkológií –⁠ áno či nie? Klin Onkol 2006; 19 (3): 167–170.

38. Hronek M, Kudláčková Z, Jílek P et al. Probiotika v profylaxi a terapii nádorových onemocnění a vulvovaginitid. Prakt Lékáren 2006; 2 (2): 63–65.

39. Hronek M, Kudláčková Z, Nekvindová J. Probiotika a prebiotika v profylaxi a terapii poruch GIT a V prevenci karcinogeneze. Farmacie pro Praxi 2006; 1 : 41–42.

40. Gouriet F, Million M, Henri M et al. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis 2012; 31 (9) : 2469 –⁠ 2480. doi: 10.1007/ s10096-012-1599-5.

41. Janák D, Bakalář B, Fridrichová M et al. When probiotics turn deadly: a case of Lacticaseibacillus rhamnosus sepsis in a burn patient. Folia Microbiol (Praha) 2026. [Ahead of Print]. doi: 10.1007/s12223-026-01445-x.